Reducing heart disease risk in type 1 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years or older and have had type 1 diabetes for more than 10 years.
- You must have kidney disease, a history of heart problems, heart failure, severe obesity, or a high heart disease risk score.
- You cannot have type 2 diabetes, MODY, or diabetes caused by other conditions.
- If you are a woman able to become pregnant, you must use highly effective birth control during the study and for 2 months after.
- You cannot have advanced kidney disease (stage 5) or a history of pancreatitis.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
This study tests whether sitagliptin can delay or prevent type 1 diabetes in people who have a close family member with type 1 diabetes and early “at-risk” blood test results. It focuses on relatives who have early immune markers and abnormal sugar testing, but are not yet diagnosed with type 1 diabetes.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.